About: Significance of new lung infiltrates in outpatients after lung and heart

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Significance of new lung infiltrates in outpatients after lung and heart–lung transplantation Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Significance of new lung infiltrates in outpatients after lung and heart–lung transplantation
Creator	Welte, T Gottlieb, J Dierich, M Greer, M Haverich, A Iaz-Ravetllat, V Iaz-Ravetllat, Vanessa Significance, Warnecke, G
Source	PMC
abstract	BACKGROUND: Infection and rejection represent major complications following lung transplantation and are often associated with pulmonary infiltrates. The differential diagnosis of these infiltrates depends on their timing after transplantation. The aim of this study was to characterize lung transplant recipients (LTR) presenting with new pulmonary infiltrates. METHODS: A retrospective analysis of all LTR and heart–lung transplant recipients attending outpatient follow‐up at our institution between September 1, 2006 and October 14, 2011 was performed. All patients presenting with new pulmonary infiltrates on chest x‐ray who underwent bronchoscopy were included. RESULTS: A total of 913 patients accounted for 13,156 attendances, with 3,912 bronchoscopies being performed. Seventy‐eight patients (9%) exhibited new pulmonary infiltrates and proceeded to bronchoscopy. Infiltrates occurred at a median 15 (interquartile range [IQR] 5–39) months after transplantation. Forty‐eight patients (62%) were male, and median patient age was 47 (IQR 29–57) years. Subsequent investigation revealed pneumonia to be the underlying cause in 63 patients (81%). In the remaining patients, chronic lung allograft dysfunction (CLAD) was responsible in 6 (8%), acute rejection in 5 (6%), and toxic pneumonitis in 4 (5%) patients. Overall 1‐year survival in LTR presenting with new infiltrates was 97%, compared with 96% for all LTR attending our Outpatient Department. CONCLUSIONS: New pulmonary infiltrates occurring after the first month in LTR are most likely due to infection. Through prompt diagnosis and treatment, early mortality appears unaffected. Late mortality remains attributable to CLAD.
has issue date	2014-04-12(xsd:dateTime)
bibo:doi	10.1111/tid.12209
bibo:pmid	24725092
has license	no-cc
sha1sum (hex)	f03560dd2e5d14db5ebed6b0730ff517b504cbcc
schema:url	https://doi.org/10.1111/tid.12209
resource representing a document's title	Significance of new lung infiltrates in outpatients after lung and heart–lung transplantation
has PubMed Central identifier	PMC7169667
has PubMed identifier	24725092
schema:publication	Transpl Infect Dis
resource representing a document's body	covid:f03560dd2e5d14db5ebed6b0730ff517b504cbcc#body_text
is schema:about of	named entity 'pneumonia' named entity 'dysfunction' named entity 'Abstract' named entity 'pulmonary' named entity 'LTR' named entity 'Significance' named entity 'lung' named entity 'STUDY' named entity 'CHEST X-RAY' named entity 'CLAD' named entity 'INFECTION' named entity 'INFECT' named entity 'CAUSE' covid:arg/f03560dd2e5d14db5ebed6b0730ff517b504cbcc named entity 'male' named entity 'study' named entity 'LTR' named entity 'patients' named entity 'allograft' named entity 'The' named entity 'complications' named entity 'aim' named entity 'Declaration of Helsinki' named entity 'LTR' named entity 'outpatients' named entity 'outpatient' named entity 'bronchoscopies' named entity 'pneumonia' named entity 'acute rejection' named entity 'heart-lung transplant' named entity 'Infection' named entity 'heart-lung transplantation' named entity 'lung' named entity 'lung transplant' named entity 'interquartile range' named entity 'lung' named entity 'histologically' named entity 'CFU' named entity 'blood culture' named entity 'C-reactive protein' named entity 'vascular obstruction' named entity 'procalcitonin' named entity 'pulmonary toxicity' named entity 'FEV1' named entity 'sample size' named entity 'leukocyte count' named entity 'outpatient' named entity 'treatment algorithm' named entity 'SOT' named entity 'pneumonia' named entity 'bronchoscopy' named entity 'American Thoracic Society' named entity 'pneumonia' named entity 'Drug-related' named entity 'lung disease' named entity 'CMV' named entity 'lung biopsy' named entity 'itraconazole' named entity 'corticosteroids' named entity 'bronchoscopies' named entity 'valganciclovir' named entity 'colony-forming units' named entity 'pulmonary embolism' named entity 'neutrophilia' named entity 'endoscopic' named entity 'control group' named entity 'Pneumocystis jirovecii' named entity 'differential diagnosis' named entity 'neoplasm' named entity 'antibiotics' named entity 'galactomannan' named entity 'heart-lung transplant' named entity 'early diagnosis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software